Summary We have studied the influence of the peripheral vasodilator hydralazine (HDZ) on the vasculature and blood perfusion of two members of a series of subcutaneous murine adenocarcinomata of the colon (MAC tumours), and the influence of HDZ on the efficacy and/or toxicity of TCNU and melphalan. The fluorescent DNA stain Hoechst 33342, showed that HDZ caused a shutdown of tumour vasculature, related in magnitude to both dose and tumour differentiation state; 10 mg kg-' caused an 80% vascular shutdown of well differentiated MAC 26 tumours, but only a 50% shutdown of the poorly differentiated MAC 15A tumours. 2.5 mg kg-' was ineffective. The blood perfusion marker 99mTc-HMPAO showed that the normal perfusion of MAC tumours was consistently markedly less than that of lung, liver or kidneys (4-5% of lung perfusion). HDZ (10 mg kg-') decreased MAC 26 perfusion by 63%, and that of MAC 15A by 20%. Again, 2.5 mg kg-') was ineffective. Use of in vivo to in vitro clonogenic assays showed that HDZ (10 mg kg-') potentiated the efficacy of melphalan ( -Omg kg-' i.p.) by a factor of 2.1, and increased the efficacy of TCNU ( -1O mg kg-' i.v., factor = 1.7) when given 10 or 15 min respectively after dosing. However, the addition of HDZ increased the acute bone marrow toxicity of melphalan, but not that of TCNU. The clinical relevance of these results is discussed.
An important factor influencing the delivery and therefore effectiveness of antitumour agents is the relative perfusion of tumour and other tissues with blood. It has been known for more than 40 years (Algire & Legallais, 1951 ) that perfusion of experimental tumours can be manipulated by the use of vasoactive agents, and a recent paper (Hirst & Wood, 1989) cites more than 25 compounds with the demonstrated ability to alter experimental tumour blood flow, the majority of these causing a decrease.
Typical of these is the antihypertensive hydralazine (HDZ), which has been shown to decrease the blood flow through experimental tumours when administered at doses ranging from 0.5-10 mg kg-' either intraperitoneally (i.p.) (Brown 1987; Babbs et al., 1982) or intravenously (i.v.) (Chan et al., 1984; . The results presented for the influence of lower doses of HDZ appear contradictory: Kalmus et al. (1990) showed that 0.25 mg kg-' HDZ slightly increased the blood flow through FSall tumours when administered i.p., whereas Brown (1987) , showed that, at this dose, HDZ caused a slight decrease in the blood flow through SCCVII tumours. The influence of HDZ on tumour blood flow is thought to be mainly via two mechanisms: firstly the blood vessels within most experimental tumours cannot be dilated because they are poorly formed, lacking smooth muscle and innervation (Denekamp, 1986; Chaplin, 1987) , and maximally dilated already (Chaplin, 1987) , and secondly, if the level of the arterial blood pressure drops below that of the intratumoural interstitial pressure (reported to be abnormally high (Wiig et al., 1982) ), the tumour vasculature will collapse. Also contributing are secondary effects such as the induction of red blood cell rigidity at low pH and homeostatic mechanisms diverting blood flow to critical organs and away from the extremities (Kalmus et al., 1990) . Overall, the effect of HDZ will be to cause both an absolute and relative decrease in tumour perfusion (Chan et al., 1984; Jirtle, 1988) .
HDZ has also been shown to enhance the effectiveness of 'bioreductive' agents such as the nitroimidazole RSU 1069 (Chaplin & Acker, 1987) and the benzotriazine di-N-oxide SR 4233 (Brown, 1987) , and to increase the efficacy and therapeutic index of the bifunctional nitrogen mustard, L- phenylalanine mustard (melphalan) (Stratford et al., 1988) .
In the case of melphalan, it was suggested that HDZ decreased the rate of tumour clearance, improving melphalan efficacy by increasing the exposure of tumour cells (Stratford et al., 1987 (Stratford et al., , 1988 has been shown to be a good model for clinical large bowel cancer in terms of range of histology and chemosensitivity . These two agents were used to investigate the influence of HDZ on the vasculature and perfusion of these MAC tumours. We investigated by the use of both in vivo to in vitro clonogenic assays and in vivo tumour growth inhibition assays the influence of HDZ on the efficacy of both melphalan and tauromustine (TCNU) against tumours. TCNU (1-(2-chloroethyl) -3-[2-(dimethyl-amino-sulphonyl) ethyl]-1-nitrosourea) is a novel nitrosourea shown to have good activity both clinically (Smyth et al., 1987; Gundersen et al., 1989) and against the MAC tumours , (also reviewed in Workman, 1987) , whose dose limiting toxicity in patients is myelosuppression (Smyth et al., 1987; Gundersen et al., 1989) . A positive correlation has been demonstrated between the in vivo and in vitro sensitivity of the MAC tumours to TCNU (Phillips et al., 1988 99Tc-HMPAO The use of 9'Tc-HMPAO to measure clinical (Holmes et al., 1985; Ell et al., 1985; Rowell et al., 1990) , and experimental (Hammersley et al., 1987 ) blood flow has been described. This technique relies on the principle, first described by Sapirstein (1956) that, for a given time after its intravenous administration, the fractional distribution of an indicator among the organs will correspond to the fractional distribution of the cardiac output amongst them. Work-up experiments using non-tumour bearing NMRI mice showed that relative tissue levels of 99mTc-HMPAO remained constant between 10 min and 1 h after administration, and that the radiochemical purity of the`mTc-HMPAO was not significantly reduced for at least an hour after the addition of the 99mTc.
Non-anaesthetised mice were killed by cervical dislocation 10 min after i.v. administration of 37 kBq of 99mTc-HMPAO (0.1 ml). Lung, liver, kidney, tumour and tail tissues were removed. The lungs were washed by brief immersion in isoton to remove any surface blood contamination and then blotted. All tissues were weighed, and the radioactivity present in each tissue/organ measured by use of a Wallac 1282 Compugamma Gamma Counter. The radioactivity/g tissue was then calculated for each sample and results normalised for radioactivity remaining in the tails, and for radioactive decay during both the experiment and sample assay. From this adjusted figure, the relative distribution of blood was deduced.
The time course of the effects of HDZ on relative tissue/ organ perfusion was studied by injecting either non-tumour bearing mice, or those bearing MAC 26 or MAC 15A tumours with`mTc-HMPAO 5 min, 1, 2 or 4 h after administration of 1O mg kg-' HDZ, and then proceeding as above. For inter-experiment comparisons, results were expressed as percentages of control values, which were obtained from animals which had received only 9'Tc-HMPAO. Examina- tion of the data obtained showed that the absolute values of counts/g tissue varied between experiments. This was due to expected alterations in the radioactivity of different batches of 99'Tc-HMPAO. However, the lungs consistently had the highest counts/g tissue. Therefore, for intra-experimental comparisons, the lungs were arbitrarily selected as a reference tissue against which to compare the other tissues. All results were compared to a control experiment, where non-tumour bearing animals were injected with saline (1 ml per 100 g bodyweight), and then 99'Tc-HMPAO according to the time schedule described above.
The relationship between HDZ dose and perfusion was investigated for both tumours. 99ITc-HMPAO was administered 5 min after HDZ (2.5 or 10 mg kg-'), and the assessment of perfusion made as above.
Measurement of tumour chemosensitivity
Clonogenic assays This method was used to investigate the influence of HDZ on the efficacy of TCNU (1-20 mg kg-') and melphalan (1-10 mg kg-') against MAC 15A tumours. HDZ was administered 10 min after the TCNU, which is the time of peak tumour concentration in NMRI mice , and 15 min after the melphalan, which is the time of peak plasma concentration in C3H mice (Lee & Workman, 1986 (Geran et al., 1972) . Volume measurements for each tumour were normalised to their initial values, and a calculation made of the time taken for the tumours to reach a relative tumour volume of 2 (RTV2). The chemosensitivity of the rapidly growing MAC 15A tumours was assessed in terms of both tumour weight inhibition at 7 days after treatment (Bibby et al., 1989b ) and time to reach RTV2.
Bone marrow toxicity
In vivo colony forming units-spleen (CFU-S) assay An adaptation of the method of Till & McCulloch (1961) was used to assess in vivo the influence of HDZ on the acute bone marrow toxicity of TCNU (2.5-30mg kg-') or melphalan (2.5 or 5 mg kg-') in mice bearing MAC 15A tumours (two per group). HDZ (10 mg kg-') was administered O min after the TCNU or 15 min after the melphalan, and bone marrow toxicity assessed 24 h after the last dose. Each experiment involved investigating one drug concentration with or without HDZ.
Removal of bone marrow Bone marrow was aspirated from both femora of each pair of mice by flushing with 1-2 ml HBSS. These individual suspensions were pooled to give one per group. An additional control suspension was obtained from two untreated mice for each drug level tested. These marrow suspensions were made up to 10 ml and stored on ice until injection, which was always within 1 h of removal from the animal. The number of cells in each suspension was counted using a Neubauer haemocytometer and dilutions made to give approximately 106 cells ml -'. These diluted cell suspensions were then injected (0.2 ml mouse-' i.v.) into groups of 5-6 mice which had previously been anaesthetised (Saffan 36 mg kg-' or ether) and exposed to supralethal X-irradiation (11.7 Gy mouse-'). Seven days later these mice were killed, their spleens removed, fixed in Bouin's fluid and the number of surface colonies counted. The surviving fraction was calculated as the number of colonies observed in the treated groups compared with those in the control.
Statistical analysis
Differences between control and treated groups were quantified by use of a two tailed un-paired students t-test. The results obtained by the use of 99mTc-HMPAO showed that the perfusion of the normal tissues studied was consistently in the rank order: lungs > kidneys > liver, with the tumour tissues being considerably less well perfused than the liver tissue, (Figure 2 +0.043. It was found that 20mg kg-' TCNU gave a per cent survival of 0 when administered without HDZ. Therefore the data presented in Figure 5b is for 1 -O mg kg-'.
In vivo assay The addition of HDZ (10 mg kg-') increased the time taken for MAC 26 tumours administered with melphalan (10 mg kg-') to reach a relative tumour volume of 2 (RTV2) from 8.7 ± 2.1 to 15.5 ± 1.1 days, an increase by a factor of 1.8. HDZ (10 mg kg-') also caused a dose related enhancement of the efficacy of melphalan against MAC 15A tumours, whether the results are expressed in terms of tumour weight inhibition, or of the time taken for tumours to reach RTV2 (Table I) . Melphalan alone caused a 43 ± 13% reduction in tumour weight, and delayed the time to RTV2 from 2.8 ± 0.5 to 4.1 ± 0.6 days. The addition of HDZ (1Omg kg-') increased the tumour weight inhibition, by a factor of 1.6, to 70 ± 16% (P<0.01), and delayed the time to RTV2, by a factor of 2.5, from 4.1 ± 0.6 to 10.3 ± 5.3 (P<0.01). HDZ (2.5 mg kg-') was ineffective. HDZ (10 mg kg-') did not significantly alter the efficacy of TCNU (30 mg kg-') against either MAC 26 tumours (data not shown), or MAC 15A tumours (Table I) . TCNU alone increased the time for MAC 15A tumours to reach RTV2 from 2.5 ± 1.0 days to 6.3 ± 2.1 days. After the addition of HDZ, the time to RTV2 was 6.1 ± 1.9 days.
Bone marrow toxicity assay HDZ (10 mg kg-') did not alter the acute toxicity of TCNU (2.5-15 mg kg-') against murine bone marrow stem cells (data not shown), but did increase that of melphalan (5 mg kg-') on both occasions that this experiment was carried out (Table II (Murray et al. 1987) have also been shown to alter drug pharmacokinetics (Randhawa et al., 1985) , and it is to this latter ability that the chemopotentiation has been attributed (Randhawa et al., 1985) . The potentiation of CCNU by misonidazole has also been explained on the basis of altered pharmacokinetics (Siemann, 1990) . However, additional factors may be the existing tumour hypoxic fraction and the fact that tumour vascular shutdown would alter both intratumoural pH and hypoxia. The importance of these factors would vary with the activity/potentiation of different drugs, depending on their physicochemical properties.
Hydralazine (5 or 10 mg kg-') has been shown to cause the mean arterial blood pressure (MABP) of mice to decrease by 41-46% (Bibby et al., 1989a) . This is similar to the values presented elsewhere (Horsman 1989; Okunieff et al., 1989) .
However, the lack of lethality observed in this study and others (Stratford et al., 1988; Okunieff et al., 1989) confirms that the decreased arterial blood pressure is adequately compensated for by the selectively increased rate of perfusion of critical normal tissues. Even so, a >40% decrease in MABP is obviously clinically unacceptable. Decreased MABP is likely to be the explanation for the observation that in NMRI mice, HDZ (10 mg kg-') causes decreases in glomerular filtration rate (GFR), as measured by insulin clearance, resulting in decreased TCNU clearance from plasma and tissues (Bibby et al., 1992) . Honess & Bleehen (1991) demonstrated similar alterations in GFR by 5 mg kg-' HDZ in C3H mice. This systemic influence of HDZ not only results in increased drug AUC, but will also have a significant effect on drug metabolism. The degree of potentiation is likely to vary depending on the role of metabolism in the activity of a particular agent, and with the site where metabolism occurs. Nevertheless, on the basis of these observations, in this study the greatest potentiation of antitumour activity should have been seen in those tumours where there was the greatest vascular shutdown. The data for TCNU are contrary to this. It is well known that the sensitivity of cells (Lunn et al., 1989) . So, even though MAC 26 tumours are less resistant to TCNU than to other nitrosoureas, a fact which is thought to be due to the increased water solubility of TCNU, it will not be possible to increase the activity of TCNU by the use of HDZ, unless the increase is sufficient to saturate the ability of AT to prevent the formation of DNA-interstrand crosslinks. We have some evidence in support of this theory in the form of results obtained from preliminary investigations of the ability of HDZ to increase the activity of TCNU against MAC 13 tumours, which Lunn et al. (1989) demonstrated to have particularly low levels of AT. We found that there was a significant (P <0.05%) increase in TCNU antitumour activity when measured in terms of tumour weight inhibition at 14 days.
There are several important factors that must be borne in mind when considering the clinical relevance of the results described in this paper. The first is that, in common with most other investigations of the perfusion/vasculature of experimental tumours, all of the tumours used here were grown subcutaneously. While the MAC system of tumours has been shown to be a good model for clinical large bowel cancer in terms of other relevant parameters, it remains to be established if the vascular supply of tumours grown in this superficial site is as representative . Field et al. (1991) showed that HDZ (5 mg kg-' i.p.) caused a decrease in the blood flow through a group of transplanted malignant fibrous histiocytomas, whereas the primary tumour from which they were derived did not respond. Rowell et al. (1990) showed by the use of SPECT and 99'Tc-HMPAO that single dose oral HDZ (0.37-2.86 mg kg-') caused the blood flow through clinical lung tumours to increase rather than decrease. These results highlight the importance of selecting a clinically relevant model for investigation of the influence of vasoactive drugs on antitumour activity.
In conclusion, this study has investigated the vasculature and perfusion of two members of the panel of MAC tumours. We have shown that there are direct relationships between differentiation state and degree of vascularisation and between vascular patterns and tumour architecture in the two tumours described here. We have also demonstrated that the normal perfusion of these tumours was consistently markedly less than that of lung, liver or kidneys. Intravenous administration of HDZ caused a shutdown of tumour vasculature and a decrease in tumour perfusion, the magnitude of both of which was related to dose and tumour differentiation state. Use of in vivo to in vitro clonogenic assays showed that HDZ potentiated the efficacy of melphalan, and slightly enhanced the efficacy of TCNU when given 10 or 15 min respectively after dosing. However, the addition of HDZ increased the acute bone marrow toxicity of melphalan, but did not alter that of TCNU. Thus the enhancement of the efficacy of TCNU represents a true therapeutic gain, whereas the increase of melphalan activity does not. Further work is required to investigate the vasculature, perfusion and response to chemotherapy/ vasoactives of these tumours at more clinically relevant sites.
